--- title: "aTyr Pharma (ATYR) news: reverse split and class action" url: "https://aibio.space/companies/atyr-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ATYR reverse split and class action news: aTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29. aTyr Pharma, Inc." --- ATYR aTyr Pharma, Inc. NASDAQ · United States # aTyr Pharma (ATYR) news ATYR reverse split and class action news Listings · 2026-10-27 ## [aTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29](https://aibio.space/news/atyr-pharma-sets-1-40-reverse-split-shares-trade-adjusted-october-29/) The split cuts aTyr's outstanding common stock from approximately 100.5 million shares to approximately 2.5 million. The 8-K does not give a reason for the ratio. ## Latest aTyr Pharma news 1. 2026-08-07 Legal [aTyr Pharma moves to dismiss amended class action over efzofitimod statements](https://aibio.space/news/atyr-pharma-moves-dismiss-amended-class-action-efzofitimod-statements/) Defendants: aTyr Pharma, CEO Sanjay Shukla and, since May, CFO Jill M. Broadfoot. The July 17 motion to dismiss targets the amended complaint; aTyr committed on August 7 to cut 60% of staff. 2. 2026-06-08 Listings [aTyr Pharma gets 180 more days from Nasdaq to meet $1.00 minimum bid price](https://aibio.space/news/atyr-pharma-gets-180-more-days-nasdaq-meet-1-00-minimum-bid-price/) Nasdaq gave aTyr Pharma until November 30, 2026 to regain the $1.00 minimum bid price, and the company says it may use a reverse stock split. Its lead drug missed the primary endpoint of its Phase 3 trial in September 2025. ## aTyr Pharma at a glance - **Ticker**: ATYR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $57.4 million ### Related companies - [Immuneering](https://aibio.space/companies/immuneering/) NASDAQ: IMRX - [Biohaven](https://aibio.space/companies/biohaven/) NYSE: BHVN - [ImmunityBio](https://aibio.space/companies/immunitybio/) NASDAQ: IBRX - [Vicapsys Life Sciences](https://aibio.space/companies/vicapsys-life-sciences/) OTC: VICP - [Biogen](https://aibio.space/companies/biogen/) NASDAQ: BIIB - [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) NASDAQ: TENX - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) NASDAQ: AMRX - [CytomX Therapeutics](https://aibio.space/companies/cytomx-therapeutics/) NASDAQ: CTMX ### Also on NASDAQ - [Bioventus](https://aibio.space/companies/bioventus/) BVS - [IMMUCELL CORP /DE/](https://aibio.space/companies/immucell-de/) ICCC - [Erasca](https://aibio.space/companies/erasca/) ERAS - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) AMRX - [Lunai Bioworks](https://aibio.space/companies/lunai-bioworks/) LNAI - [Monte Rosa Therapeutics](https://aibio.space/companies/monte-rosa-therapeutics/) GLUE ## What aTyr Pharma does aTyr Pharma is a clinical stage biotechnology company that describes its work as leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its discovery platform uses a proprietary library of domains derived from all 20 tRNA synthetases to uncover signaling pathways. Its lead therapeutic candidate, efzofitimod, is a novel biologic. The Phase 3 EFZO-FIT study is a randomized, double-blind, placebo-controlled trial of efzofitimod in patients with pulmonary sarcoidosis. The filing states that there is no established FDA regulatory pathway for approval of a drug in pulmonary sarcoidosis, and that a Phase 3 trial missing its primary endpoint may not support approval. aTyr describes itself as a pre-commercial company that has incurred significant losses since its inception. It depends on existing collaborations and may need more partners to develop and commercialize certain candidates. It also relies on contracted manufacturers, which can face stoppages, and says it will need to raise additional capital or enter into strategic partnering relationships to fund its operations. | Product or program | What it is | Stage | |---|---|---| | Efzofitimod | Novel biologic for pulmonary sarcoidosis and fibrosis-related inflammation | Phase 3 | Summarised from the company's [10-K filed Mar 5, 2026](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm). ## aTyr Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$190,000](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) | [$235,000](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) | | Research and development | [$60.2 million](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) | [$54.4 million](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) | | Net income (loss) | [-$74.1 million](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) | [-$64.0 million](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) | | Cash from operations | [-$62.0 million](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) | [-$69.1 million](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) | | Cash and equivalents | [$10.7 million](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000053/) | [$11.1 million](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) | | Short-term investments | [$67.9 million](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000053/) | [$61.1 million](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $16.2 million, plus short-term investments of $41.3 million, $57.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about aTyr Pharma Did aTyr Pharma do a reverse stock split? Our latest story on this, dated Oct 27, 2026: "aTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/atyr-pharma-sets-1-40-reverse-split-shares-trade-adjusted-october-29/). Is there a class action against aTyr Pharma? Our latest story on this, dated Aug 7, 2026: "aTyr Pharma moves to dismiss amended class action over efzofitimod statements". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/atyr-pharma-moves-dismiss-amended-class-action-efzofitimod-statements/). What is the ticker symbol of aTyr Pharma? aTyr Pharma, Inc. trades under the ticker ATYR on NASDAQ. Where is aTyr Pharma listed? aTyr Pharma, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:471A; LS:A2PM86; LSX:A2PM86. What is the SEC CIK of aTyr Pharma? The SEC Central Index Key (CIK) for aTyr Pharma, Inc. is 1339970. Its filings are on SEC EDGAR. How many shares does aTyr Pharma have outstanding? 98,087,425 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is aTyr Pharma listed under? Our directory records aTyr Pharma, Inc. under United States. What does aTyr Pharma do? Our directory classifies aTyr Pharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of aTyr Pharma? The ISIN recorded for aTyr Pharma, Inc. is US0021202025. Does aibio.space cover aTyr Pharma? aibio.space lists aTyr Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is aTyr Pharma incorporated? SEC records list its state or country of incorporation as DE. What does aTyr Pharma develop? aTyr Pharma is a clinical stage biotechnology company that describes its work as leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its discovery platform uses a proprietary library of domains derived from all 20 tRNA synthetases to uncover signaling pathways. What is Efzofitimod from aTyr Pharma? Efzofitimod: Novel biologic for pulmonary sarcoidosis and fibrosis-related inflammation Stage: Phase 3. What was aTyr Pharma's revenue last year? $190,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is aTyr Pharma profitable? aTyr Pharma, Inc. reported a net loss of $74.1 million for the fiscal year ended Dec 31, 2025, and used $62.0 million of cash in operations, per its annual report to the SEC. ## Investor discussion: aTyr Pharma Members talk about aTyr Pharma (ATYR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at aTyr Pharma, newest first. Each line links the filing it comes from. 1. 2026-10-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000071/atyr-20261027.htm) 2. 2026-10-16 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000068/atyr-20261016.htm) 3. 2026-09-11 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000061/atyr-20260911.htm) 4. 2026-08-31 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000058/atyr-20260831.htm) 5. 2026-07-31 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000042/atyr-ex99_1.htm) 6. 2026-06-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000039/atyr-20260603.htm) 7. 2025-12-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1339970/000119312525309619/atyr-20251204.htm) 8. 2025-11-06 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1339970/000119312525269587/atyr-20250930.htm) 9. 2025-08-07 Distress Reported a material impairment charge. SEC Form 8-K (Items 2.06,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1339970/000133997025000007/atyr-ex99_1.htm) 10. 2024-12-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1339970/000095017024139633/atyr-20241224.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ATYR on TradingView](https://www.tradingview.com/symbols/NASDAQ-ATYR/). ## SEC filings and registration - **SEC name**: aTYR PHARMA INC - **CIK**: 1339970 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ATYR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 10240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121 - **Phone**: 8587318389 - **Shares outstanding**: 98,087,425 as of 2026-07-31 (10-Q filed 2026-08-07) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000068/atyr-20261016.htm) filed 2026-10-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000065/atyr-20260924.htm) filed 2026-09-24 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000061/atyr-20260911.htm) filed 2026-09-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000053/atyr-20260630.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-20260807.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000042/atyr-20260730.htm) filed 2026-07-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000039/atyr-20260603.htm) filed 2026-06-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000036/atyr-20260601.htm) filed 2026-06-01 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001339970), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details aTyr Pharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ATYR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: aTyr Pharma, Inc. - **Ticker**: ATYR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US0021202025 - **Other listed symbols**: GETTEX:471A; LS:A2PM86; LSX:A2PM86 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ATYR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/atyr-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "aTyr Pharma (ATYR) news: reverse split and class action", 2026-10-31, https://aibio.space/companies/atyr-pharma/